Stryker stock has delivered a 37.0% gain over the past five years, yet the latest valuation checks suggest it is not an obvious bargain, even as an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach points to some upside versus the current share price. With the shares recently closing at US$348.15 and the company working through the financial impact of a cyberattack and order backlog, investors are now weighing a mixed valuation picture.

• Stryker’s 37.0% return over five years points to solid long term shareholder gains. This can limit how much further upside investors expect without a clear value gap.
• Continued demand for Stryker’s robotics platform and progress on clearing the order backlog can support expectations for future cash flows. At the same time, the operational and execution risks tied to cyberattack recovery may still weigh on how much investors are willing to pay for that growth.
• Stryker currently screens as undervalued on an intrinsic value estimate based on a Discounted Cash Flow approach, yet it only passes 1 of 6 valuation checks. This implies the broader metrics lean expensive rather than clearly cheap according to this score.

For investors, the debate is whether the Discounted Cash Flow intrinsic value signal or the weaker set of broader valuation checks is the better guide to what Stryker stock is worth today.

Is Stryker a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) method values Stryker based on the cash it is expected to generate for shareholders over time. For Stryker, the model starts from last twelve month free cash flow of about $4.7b and assumes that cash generation continues to grow from this base. On that basis, the 2 Stage Free Cash Flow to Equity model points to an estimated intrinsic value of about $425 per share.

Compared with the recent share price of $348.15, this implies the stock screens around 18% undervalued on this cash flow view. The recent cyberattack and ongoing order backlog help explain why the market price may still sit below this intrinsic value estimate, even after reported demand for Stryker’s robotics platform.

On the DCF numbers alone, Stryker stock currently appears undervalued relative to the cash flows implied in this model.

Our Discounted Cash Flow (DCF) analysis suggests Stryker is undervalued by 18.0%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Does Stryker Look Fairly Valued on Earnings?

P/E is a useful lens for Stryker because earnings are a key driver of how investors think about mature medical equipment businesses. Stryker currently trades at a P/E of about 35.8x, which sits above the Medical Equipment industry average of roughly 26.3x and also above the peer group average of about 31.2x.

The tailored fair P/E ratio for Stryker, which blends its growth profile, margins, size and risk factors, sits near 34.6x. That is only slightly below the current 35.8x level. The gap suggests the stock carries a premium to the broader industry, yet the premium is broadly in line with what this framework would expect for Stryker given its characteristics.

On this P/E yardstick, Stryker stock looks roughly fairly valued rather than clearly cheap or expensive.

The Stryker Narrative: What Would Justify Today's Price?

Stryker Narratives on Simply Wall St pick up where the valuation puzzle above leaves off by spelling out which paths for Stryker’s growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price, using the same assumptions that drive investor debate. Rather than relying on a single multiple or model output, each scenario lays out the key inputs behind its fair value so you can later compare those with actual results as they are reported.

Here is a chance to add your voice to the Simply Wall St community with a Narrative on Stryker that sets out a clear, number driven view on whether the company’s cyberattack recovery and order backlog efforts support today’s price. Share your thesis now so you can track how it holds up as Stryker’s future results and guidance unfold.

Do you think there's more to the story for Stryker? Head over to our Community to see what others are saying!

The Bottom Line

For Stryker, the Discounted Cash Flow (DCF) view points to some undervaluation, while the P/E based view suggests the stock is priced roughly in line with its peers once its profile is factored in. The tension between a supportive intrinsic value estimate and weaker broader valuation checks leaves the stock more like a hold for existing views than an obvious opportunity for new capital. The crux is whether cash flows evolve in a way that ultimately validates the intrinsic value estimate, or whether ongoing execution risks around cyberattack recovery and the order backlog mean the current multiple is already full enough.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.